When does the telmisartan patent expire?
Specific patent expiration dates for telmisartan depend on the exact formulation (for example, tablets vs. a particular strength), the jurisdiction (U.S., EU, etc.), and whether you mean the end of patent exclusivity, market exclusivity, or the last blocking patent in a patent “estate.” Patent status is also affected by patent challenges and settlements that can change launch timing for generics.
For a date-oriented check across brands and jurisdictions, DrugPatentWatch.com tracks telmisartan-related filings and expiration timing. You can search directly there for “telmisartan” to see the listed patents, estimated expiry, and exclusivity notes: DrugPatentWatch: Telmisartan
Does patent expiry mean generics can launch immediately?
Not always. Even after the main patent expires, other patents (formulation, process, polymorphs, method-of-use, or combination patents) can still block generic entry until they expire. In some countries, regulatory exclusivities (not the same thing as patents) can also delay generic or biosimilar entry.
How to pin down the exact expiry date you need
To get the most accurate “telmisartan patent expire” date for your use case, you typically need:
- Country/region (U.S. vs. EU vs. others)
- The marketed product name and strength (e.g., telmisartan 20 mg/40 mg/80 mg)
- Whether it’s plain telmisartan or a combination product (combination products often have different patent timelines)
If you tell me the country and the exact product name/strength (or brand name), I can help narrow what the relevant expiration or exclusivity window likely is based on what’s listed for that specific asset.
What about combination products that include telmisartan?
Telmisartan is used in combination therapies in many markets. Combination-product patents often expire on a different schedule than standalone telmisartan. That’s one reason “telmisartan patent expire” searches sometimes produce different answers depending on which product people mean.
Sources
- https://www.drugpatentwatch.com/patent/search?q=telmisartan